pharma · Syphilis · Human Immunodeficiency Virus
MEDA Pharma GmbH
MEDA Pharma GmbH & Co. KG
MEDA Pharma GmbH trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Bad Homburg, DE HQ
89 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Bad Homburg, DE
- Employees
- 89
- Programs
- 8
- Drugs
- 28
- Patents
- 0
MEDA Pharma GmbH clinical trials
Registry index of 8 ClinicalTrials.gov studies linked to MEDA Pharma GmbH programs — each row shows trial ID, program name, phase, status, and indication.
MEDA Pharma GmbH trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for MEDA Pharma GmbH.
-
BCN05-Bari — Phase 2
Clinical update -
DORALI — Approved
Clinical update -
THALASSA 2.0 — Phase 2
Clinical update -
Empagliflozin — Unknown
Clinical update -
BENZATHINE BENZYLPENICILLIN , LINEZOLID — Approved
Clinical update -
Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG — Phase 2
Clinical update -
Veklury 100 mg powder for concentrate for solution for infusion — Phase 2
Clinical update -
Pacritinib — Phase 2
Clinical update
Trial registry
-
CTIS ↗ - 2024-514330-20-00CTIS ↗
Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG
Mild Cognitive impairment due to Alzheimer Disease
-
CTIS ↗ -
CTIS ↗ - 2024-519272-96-00CTIS ↗
Veklury 100 mg powder for concentrate for solution for infusion
COVID-10 infection
-
CTIS ↗ - 2025-522509-39-00CTIS ↗
Pacritinib
Patients with myelofibrosis and platelets counts between 50 - 120 x 10e9/L
-
CT.gov ↗